Systematic Review: Antimicrobial Urinary Catheters To Prevent Catheter-Associated Urinary Tract Infection in Hospitalized Patients
Abstract
Key Summary Points Randomized or quasi-randomized clinical trials of antimicrobial urinary catheters currently marketed in the United States (i.e., nitrofurazone-coated and silver alloycoated catheters) provide little or no data on these devices' effect on symptomatic urinary tract infection, morbidity, secondary bloodstream infection, mortality rates, or associated health care costs. Both nitrofurazone-coated and silver alloycoated catheters seem to reduce the development of asymptomatic bacteriuria during short-term (<30 days) use, in comparison with latex or silicone control catheters. The magnitude of this effect varies among studies, seemingly in relation to the type of antimicrobial catheter (nitrofurazone or silver), patient sample (urology or other), control group bacteriuria rate (high or low), and type of control catheter (latex or silicone). No trials directly compared nitrofurazone-coated and silver alloycoated catheters. Therefore, assessments of the comparative efficacy of nitrofurazone-coated and silver alloycoated catheters should be made cautiously. The clinical utility and cost-effectiveness of antimicrobial urinary catheters must be assessed in well-designed, adequately powered, randomized clinical trials. Indwelling urinary catheters, which are used in 15% to 25% of short-term care patients during their hospitalization, confer a predisposition to bacteriuria (1-3). Catheter-associated urinary tract infection (UTI) is the most common type of…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 900,000 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.